ArticleJournal of bone oncology2025
hMSCs-derived exosomal MIR17HG promotes follicular helper T cell differentiation and osteosarcoma progression via the miR-372-3p/BCL6 axis.
Article in Journal of bone oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in T cell-based immunotherapy for osteosarcoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma (OS) is a life-threatening malignancy in children and adolescents, with limited treatment options for resistant or metastatic disease. Exosomes derived from hMSCs regulate tumor immunity by transporting molecules such as long non-coding RNA (lncRNA). The lncRNA MIR17HG is known to promote OS progression, yet its role in regulating T follicular helper (Tfh) cell differentiation in OS is unclear. This study is the first to systematically explore how MIR17HG influences Tfh cell differentiation, activation, and OS cell proliferation via the miR-372-3p/BCL6 signaling cascade. Methods: Exosomes were extracted from hMSCs using differential centrifugation. Characterization of hMSCs-derived exosomes was conducted by TEM, NTA and western blotting. The expression of MIR17HG, BCL6 and PD-1 was determined by qRT‒PCR or western blotting. The differentiation and activation of Tfh cells, as well as OS apoptosis, were assessed through flow cytometry. OS cell viability was determined by a CCK-8 assay. The effect of hMSCs-Exo-MIR17HG on tumors was assessed in an MG63-derived xenograft mouse model. The expression of Ki67 was examined via IHC. RNA immunoprecipitation was performed to validate the interaction between MIR17HG and miR-372-3p. A dual-luciferase reporter assay was performed to explore the correlation between miR-372-3p and BCL6. Results: The lncRNA MIR17HG was expressed in hMSCs-derived exosomes and upregulated by overexpression. hMSCs-Exo or hMSCs-Exo-MIR17HG promoted the differentiation and activation of Tfh cells, accompanied by increased PD-1 and BCL6 expression in CD4 Conclusion: These findings demonstrate that exosomal MIR17HG derived from hMSCs drives the differentiation of follicular helper T cells and the progression of OS via the miR-372-3p/BCL6 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.